Captrust Financial Advisors Sells 683 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Captrust Financial Advisors lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 66,763 shares of the medical research company's stock after selling 683 shares during the period. Captrust Financial Advisors' holdings in Thermo Fisher Scientific were worth $34,732,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Principal Financial Group Inc. raised its holdings in shares of Thermo Fisher Scientific by 22.1% in the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock worth $771,876,000 after acquiring an additional 225,568 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Thermo Fisher Scientific by 23.6% in the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock valued at $28,868,000 after purchasing an additional 10,606 shares in the last quarter. Kings Path Partners LLC grew its holdings in Thermo Fisher Scientific by 13.1% during the fourth quarter. Kings Path Partners LLC now owns 2,637 shares of the medical research company's stock worth $1,372,000 after buying an additional 306 shares in the last quarter. Doliver Advisors LP raised its position in Thermo Fisher Scientific by 1.6% in the 4th quarter. Doliver Advisors LP now owns 2,803 shares of the medical research company's stock valued at $1,458,000 after buying an additional 44 shares during the last quarter. Finally, Oliver Luxxe Assets LLC boosted its holdings in Thermo Fisher Scientific by 6.2% during the 4th quarter. Oliver Luxxe Assets LLC now owns 9,461 shares of the medical research company's stock worth $4,922,000 after acquiring an additional 555 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity

In other news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,075 shares of company stock worth $7,305,942 over the last 90 days. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Down 1.9 %

NYSE:TMO traded down $7.85 during mid-day trading on Friday, hitting $402.93. 2,318,607 shares of the company's stock were exchanged, compared to its average volume of 1,797,672. The company has a market cap of $152.10 billion, a PE ratio of 24.38, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a one year low of $401.75 and a one year high of $627.88. The business has a fifty day moving average price of $464.67 and a 200 day moving average price of $515.28.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the business posted $5.11 EPS. The firm's quarterly revenue was up .2% compared to the same quarter last year. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific's payout ratio is 10.09%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on TMO shares. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Evercore ISI decreased their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Finally, Barclays decreased their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $607.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.